Skip to main content
About
Contact
Subscribe
e-Edition
Make Home Page
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Twitter
Toggle navigation
Site search
Search
Home
Contact Us
Advertise
Subscription Services
Promote Your Event
Submission Forms
News
Local News
National
World
Archives
Sports
Local Sports
National Sports
Business
Local Business
National Business
Technology
Markets & Stocks
Opinion
Columns
Editorials
Letters To The Editor
Polls
Thumbs
A & E
Local Entertainment
Art Scene
Music Scene
Theatre Scene
Book Reviews
Movie Reviews
TV Listings
Local Events
What To Do
Life
Health
Travel
Oddities
Food Scene
Community Directory
Community Service
Restaurant Guide
Rescue Me
Other
Specials
Entertainment Now
Spring Wellness
Home & Garden
Home Improvement
Home & Realty
Horizons
Outdoor Guide
Progress
Women
Classifieds
Place Ad
Careers
Tenders
Weather
Obituaries
Parcel Services
2021 Readers Choice Winners
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Theravance Bio Ord
(NQ:
TBPH
)
8.980
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, May 25, 2022
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
0
Open
8.980
Bid (Size)
0.9000 (2)
Ask (Size)
17.00 (1)
Prev. Close
8.980
Today's Range
8.980 - 8.980
52wk Range
6.100 - 18.83
Shares Outstanding
76,115,393
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
Top News
More News
Benzinga's Top Ratings Upgrades, Downgrades For May 23, 2022
May 23, 2022
Via
Benzinga
The Daily Biotech Pulse: AstraZeneca's 3 Product Updates, Jazz Pharma Licenses Sleeping Disorder Product, Argenx Aces Bleeding Disorder Study
May 05, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
Performance
YTD
-26.87%
-26.87%
1 Month
-10.38%
-10.38%
3 Month
-1.43%
-1.43%
6 Month
+6.27%
+6.27%
1 Year
-46.16%
-46.16%
More News
Read More
Theravance Biopharma's Earnings Outlook
May 04, 2022
Via
Benzinga
Theravance Biopharma's Ampreloxetine Shows Benefit In Atrophy Patients, But Not In Parkinson's
April 05, 2022
Via
Benzinga
The Daily Biotech Pulse: Thervance Gains On Positive Late-Stage Readout, Bristol-Myers Squibb Snags 3 Approvals In Europe, Decision Day For BioXcel
April 05, 2022
Via
Benzinga
Why Theravance Biopharma Stock Is Trading Lower After Hours
April 04, 2022
Via
Benzinga
World Markets News For Friday
March 18, 2022
Via
Talk Markets
Red Ink
February 24, 2022
Via
Talk Markets
Recap: Theravance Biopharma Q4 Earnings
February 24, 2022
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
February 23, 2022
Via
Benzinga
Give peace a chance
February 15, 2022
Via
Talk Markets
Earnings Scheduled For February 23, 2022
February 23, 2022
Via
Benzinga
Nuclear Winter
February 11, 2022
Via
Talk Markets
The Last Day In January
January 31, 2022
Via
Talk Markets
More Serious Matters
January 14, 2022
Via
Talk Markets
12 Health Care Stocks Moving In Wednesday's Intraday Session
January 12, 2022
Via
Benzinga
50 Biggest Movers From Yesterday
January 13, 2022
Via
Benzinga
28 Stocks Moving In Wednesday's Mid-Day Session
January 12, 2022
Via
Benzinga
48 Biggest Movers From Yesterday
January 12, 2022
Via
Benzinga
35 Stocks Moving In Monday's Mid-Day Session
January 03, 2022
Via
Benzinga
61 Biggest Movers From Yesterday
January 04, 2022
Via
Benzinga
To sell or not to sell?
December 14, 2021
Via
Talk Markets
Wednesday Global Investing Report
December 08, 2021
Via
Talk Markets
12 Health Care Stocks Moving In Wednesday's Intraday Session
December 08, 2021
Via
Benzinga
Thursday Markets Overview
December 02, 2021
Via
Talk Markets
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.
